Holiday Sale | Save 50%
SubscribeLogin
Holiday Sale | Save 50%
Published

Candel’s cancer therapy meets late-stage trial goal, shares soar

Summary by WTVB
(Reuters) -Candel Therapeutics said on Wednesday its experimental immunotherapy for prostate cancer met the main goal of a late-stage trial, helping the company’s shares more than double in value in premarket trading. The immunotherapy, CAN-2409, in combination with radiation therapy significantly improved disease-free survival in patients, compared to radiation alone, the company said. Candel said it plans to discuss with the Food and Drug Admi…
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 67% of the sources lean Left
67% Left
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Similar News Topics

Trending Topics
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble NewsletterTimelines
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2024 Snapwise Inc
News
For You
Search
BlindspotLocal